China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor

SHANGHAI and SAN FRANCISCO and WALTHAM, Mass., July 20, 2020 /PRNewswire/ — Zai Lab Limited (NASDAQ: ZLAB) and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or […]

Back To Top